LCN2 inhibits CRC metastasis via the TGFB1/CXCL5 axis and the combination of TGF-βR1 inhibitor and CXCR2 antagonist mitigates LCN2-related CRC metastasis. Here, CXCL5 is linked to colorectal carcinoma.